Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: A retrospective, cohort-controlled trial
Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: A retrospective, cohort-controlled trial
To investigate pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) safety and efficacy in preventing haematological toxicity during concurrent chemoradiotherapy (CCRT) for small-cell lung cancer (SCLC).